Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
307.10
+3.55 (1.17%)
At close: Aug 8, 2025, 4:00 PM
305.00
-2.10 (-0.68%)
After-hours: Aug 8, 2025, 5:23 PM EDT
Verve Therapeutics Revenue
Insulet had revenue of $649.10M in the quarter ending June 30, 2025, with 32.88% growth. This brings the company's revenue in the last twelve months to $2.36B, up 25.99% year-over-year. In the year 2024, Insulet had annual revenue of $2.07B with 22.07% growth.
Revenue (ttm)
$2.36B
Revenue Growth
+25.99%
P/S Ratio
9.14
Revenue / Employee
$605,000
Employees
3,900
Market Cap
21.62B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PODD News
- 2 days ago - Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5 - Benzinga
- 2 days ago - Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Insulet beats second-quarter profit estimates on strong demand for insulin pumps - Reuters
- 2 days ago - Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1) - Business Wire
- 9 days ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 19 days ago - 15 stocks of companies set to grow sales twice as fast as the S&P 500 — analysts love them - Market Watch
- 4 weeks ago - Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 7 weeks ago - Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions - Business Wire